Background The overall prognosis and survival of patients with advanced gastric cancer are generally poor. Extended lymphadenectomy is recommended for patients with advanced gastric cancer; however, splenectomy and distal pancreatectomy performed with an extended lymph node dissection may be associated with increased morbidity and mortality. Method Electronic literature searches were conducted using Medline, Embase, and the Cochrane Central Register of Controlled Trials from 1 January 1998 to 31 December 2009. Studies on gastric carcinoma investigating extended lymphadenectomy with splenectomy and/or pancreaticosplenectomy that reported data on surgical outcomes or survival were selected. Results Forty studies were included in this review. Decreased complication rates were demonstrated with spleen preservation in two prospective studies and three retrospective studies, and with pancreas preservation in five retrospective studies. No randomized controlled trial showed survival benefit or detriment for preservation of spleen or pancreas in extended lymphadenectomy. Improved survival was demonstrated with spleen preservation in two prospective and eight retrospective studies, and with pancreas preservation in one prospective and four retrospective studies. Conclusions Preservation of the spleen and pancreas during extended lymphadenectomy for gastric cancer decreases complications with no clear evidence of improvement or detriment to overall survival.
Introduction
Adequate surgical resection remains the foundation of curative therapy for patients with gastric cancer. Lymphadenectomy is considered essential for gastric cancer surgery; however, the extent of lymph node removal is still debated in the literature [1] [2] [3] [4] [5] [6] . In Asia, extended lymph node dissection has long been the standard of care for patients with advanced gastric cancer [7] [8] [9] [10] . D2 lymphadenectomy, which includes recovery of the lymph nodes from along the splenic artery and the splenic hilum, is widely accepted in Asia as both safe and necessary. Spread of malignant cells to the nodes along the splenic artery and within the hilum has been reported to occur in a significant proportion of patients with gastric cancer and has been cited as a harbinger of poor prognosis [8, 11] . Lymphogram imaging studies support the notion that gastric cancer in the proximal third of the stomach preferentially drains to the lymph nodes of the splenic artery and hilum [12] . Historically, 20-30% of patients with proximal gastric cancer had metastases to the lymph nodes in the splenic hilum [13] . Distal gastric cancers, on the other hand, rarely have involvement of these lymph nodes [14] . The historical D2 lymphadenectomy included both splenectomy and distal pancreatectomy for adequate clearance of these nodes, and this approach was supported by early reports in the 1980s from the Japanese literature [14] . Furthermore, several authors state that resection of the spleen and pancreas may be necessary in patients with advanced disease, such as positive lymph nodes along the splenic artery [8, [14] [15] [16] [17] [18] or T3 disease [18] [19] [20] . However, resection of the spleen and distal pancreas is a technically demanding component of the extended lymphadenectomy and results in increased complications, especially pancreatic fistula [11, 14, 17, [21] [22] [23] .
Two large multicenter randomized trials (RCTs), the Medical Research Council (MRC), Gastric Cancer Surgical Trial and the Dutch Gastric Cancer Trial (DGCT), were conducted in the 1990s to examine the benefit of extended lymphadenectomy in curative gastrectomy for patients with gastric cancer [1, 2] . Initially, these RCTs reported that a D2 lymphadenectomy did not result in improved survival. Patient selection, surgeon inexperience, and lack of quality control measures have been proposed to explain the discrepancies between these findings and the experience in Asia, and in particular why these two RCTs reported increased morbidity and mortality with D2 lymphadenectomy [13, 21] . In subgroup analysis, increased postoperative morbidity and mortality were felt to be attributable to the resection of the spleen and pancreas during extended lymphadenectomy [2, 24] . In the DGCT, all patients randomized to D2 lymphadenectomy were required to have resection of the spleen and pancreas, though neither was resected in 62% of patients in the D2 arm of the trial [1] . In the MRC trial, resection of the spleen and pancreas with D2 lymphadenectomy was required in patients with cancers in the middle or upper third of the stomach, and neither was resected in 35% of patients in this arm of the trial [25] . Preservation of the spleen and pancreas during D2 lymphadenectomy has been advocated by the authors of the DGCT-recommendations that were made on the basis of post-hoc subgroup analysis and must be interpreted accordingly [24] . Despite assertions from both trials that resection of the spleen and pancreas in the D2 arm was responsible for increased operative morbidity and mortality, no RCT has shown a survival advantage when performing pancreas-preserving or spleen-preserving D2 resection compared to the traditional D2 resection [26] [27] [28] . In addition, the role of the spleen in cancer immunology has been cited as a reason to consider spleen preservation during extended lymphadenectomy [12] .
Despite these concerns regarding splenectomy and pancreaticosplenectomy, these procedures continue to be performed alongside extended lymphadenectomy for gastric cancer [29, 30] . The current Japanese Gastric Cancer Association guidelines recommend that D2 lymphadenectomy with splenectomy be considered for patients with T2-T4 tumors along the greater curvature of the upper stomach [31] . Conversely, other groups recommend selective performance of splenectomy or distal pancreatectomy [32] . These groups argue that preservation of the spleen and pancreas has no detrimental effect on survival. Given these conflicting views, we present a systematic review of the evidence for preservation of the spleen and pancreas in extended lymphadenectomy during surgical therapy for gastric cancer.
Methods

Data sources
Electronic literature searches were conducted in Medline and EMBASE from 1 January 1998 to 31 
Study selection and review process
To be eligible, studies had to meet the following criteria: (1) investigation of splenectomy and/or pancreaticosplenectomy in newly (not recurrent) diagnosed patients with histopathology confirmed gastric adenocarcinoma; (2) patients underwent surgery, and complication or survival data were reported; (3) involved human subjects with a minimum of 30 patients; (4) published in peer-reviewed journals from 1998 to 2009; (5) published in English. Studies were excluded according to the following exclusion criteria: (1) involved animals and/or ex vivo samples; (2) involved patients with mixed cancer or studies investigating splenectomy and/or pancreaticosplenectomy in other cancers with no separate analysis of gastric cancer subjects; (3) studies that did not provide sufficient information to determine complication or survival data; (4) review articles, meta-analyses, abstracts, conference proceedings, editorials/letters, and case reports. All electronic search titles, selected abstracts, and full-text article were independently reviewed by a minimum of two reviewers (NC, LH, RC, RS). Reference lists from review papers and relevant articles were also examined for additional studies that met our inclusion criteria. Disagreements on study inclusion/exclusion were resolved with a consensus meeting of the reviewers.
Data extraction
A systematic approach to data extraction was used to produce a descriptive summary of participants, interventions, and study findings. Data abstracted included the type of study, number of patients, age, gender, TMN stage, and details of the type of resection. Surgical outcomes, including the number of lymph nodes examined, presence or absence of residual tumor (R0 status), operative time, need for reoperation, length of hospital stay, postoperative complications, and operative or hospital mortality, were extracted. Survival data including length of follow-up, overall survival and survival by subgroups were extracted. The first reviewer (RS) independently extracted the data, and a second reviewer (SB) checked the data extraction. No attempt was made to contact authors for additional information. All RCTs were assessed for quality using the Jadad scoring system [33] .
Data analysis
Randomized controlled trials were identified from the review. Statistical analysis and figure generation were performed using Review Manager 5.0 software (The Cochrane Collaboration, Copenhagen, Denmark). Using the Mantel-Haenszel method, odds ratios (OR) with 95% confidence intervals (95% CI) were calculated for dichotomous variables. P \ 0.05 was defined as significant. No sensitivity analysis was performed.
Results
Literature search
A total of 3,608 titles/abstracts were identified from the electronic searches and reference lists for preliminary review. After removal of duplicates and screening for relevant titles and abstracts, a total of 142 articles were submitted for a full-text review. A total of 40 articles involving 6,354 patients met our inclusion criteria and were included in this review (Fig. 1 ). Of these, 3 studies were RCTs comparing standard D2 lymphadenectomy with spleenpreserving D2 lymphadenectomy [26, 28, 30] (Table 1) , 1 was an RCT comparing standard D2 lymphadenectomy with pancreas-preserving D2 lymphadenectomy [27] ( Table 1) , 6 were prospective studies examining the extent of lymphadenectomy [1, 2, 9, 10, 34, 35] (Table 2) , and 32 were retrospective studies [7, 8, 11, 12, 14-19, 21-23, 29, 36-51] (Table 3 ). The four RCTs examining spleen and/or pancreas preservation were evaluated and given Jadad scores between 1 and 3 ( Table 1) . The six prospective studies on the extent of lymphadenectomy were used to identify patients undergoing D2 or D3 lymphadenectomy with and without preservation of the spleen and/or pancreas ( Table 2) .
Surgical outcomes
Data for surgical outcomes were pooled from the 40 articles included in the review. No significant difference in overall complications, pancreatic fistula, anastomotic leak, or operative mortality was found in the individual RCT results (Table 1) . A forest plot shows the meta-analysis of operative survival of the three RCTs comparing gastrectomy with spleen resection or preservation, and demonstrates no statistically significant difference (OR 1.59, 95% CI 0.44-5.79) (Fig. 2 ). In the six prospective lymphadenectomy trials, preservation of the spleen and pancreas was associated with fewer overall complications in two studies and fewer operative deaths in one study; in the remaining Spleen-pancreas preservation and gastric cancer S91 studies, the differences were non-significant or not reported (Table 2 ). In the retrospective studies, preservation of the spleen was associated with fewer complications in three studies, preservation of the pancreas was associated with fewer overall complications in five studies, and decreased operative mortality in one study. In the remaining 33 retrospective studies, there were no significant differences in complications and operative mortality in 10 spleen-preserving trials and 13 pancreas-preservation studies, respectively; however, 13 studies did not report on this.
Overall survival
Overall survival was reported in 29 studies. In the RCTs, there was no statistically significant difference between overall survival in patients who underwent extended lymphadenectomy with or without spleen preservation [26, 28, 30] (Table 1) . A forest plot illustrates the meta-analysis of overall survival of the three RCTs comparing gastrectomy with spleen resection or preservation, and demonstrates no statistically significant difference (OR 0.97, 95% CI 0.56-1.68) (Fig. 3) . Spleen preservation was associated with improved overall survival in two prospective lymphadenectomy trials, and there was no difference in another prospective lymphadenectomy trial (Table 2 ). In the retrospective studies, spleen preservation was associated with improved survival in 8 studies, diminished survival in 1 study, and no statistically significant difference in survival in 12 studies (Tables 3, 4 , 5). In the one RCT comparing patients who underwent extended lymphadenectomy with or without pancreas preservation, there was no statistically significant difference in overall survival [27] (Table 1 ).
In the prospective lymphadenectomy trials, pancreaticosplenectomy was associated with decreased survival in one study and with no difference in overall survival in two studies (Table 2) . Three prospective lymphadenectomy trials did not report survival. Two retrospective studies found pancreaticosplenectomy was associated with a statistically significant decrease in overall survival (Table 6) . Six retrospective studies reported no statistically significant difference in survival in patients who underwent D2 resection with or without pancreas resection, and an additional six studies did not report overall survival (Table 7) . Retrospective studies that report survival data with subgroup analysis are listed in Appendix B in the Electronic supplementary material. Positive lymph nodes in the splenic artery and hilum were associated with decreased survival [15, 19, 22, 44, 48] . Extended lymphadenectomy with spleen resection for patients was associated with decreased survival in one study compared to spleen preservation when these nodes were positive [44] . R0 resection was associated with improved survival in patients in two studies [14, 42] .
Discussion
For patients with gastric cancer, curative therapy rests on adequate surgical resection and lymphadenectomy. Extended lymphadenectomy is thought to improve outcomes in patients with advanced gastric cancer. However, the removal of the spleen and pancreas to facilitate lymph node harvest along the splenic artery and hilum, and not for direct invasion, has been called into question. Instead, Significance corresponds to the noted superscripts AL anastomotic leakage, EF enterocutaneous fistula, IT immunotherapy, NR not reported, NS not significant, PF pancreatic fistula, PP pancreaspreserving, PR pancreaticosplenectomy, pts patients, R0 resection with no residual tumor, SP spleen-preserving, SR splenectomy preservation of the spleen and pancreas during D2 lymphadenectomy has been proposed by some as a safer procedure with improved short-term outcomes and no detriment to long-term survival. In this review, we systematically reviewed 40 articles, both prospective and retrospective, to determine and summarize the evidence for preservation of the spleen and pancreas during extended lymphadenectomy. D2 lymphadenectomy with preservation of the spleen and pancreas is likely associated with a decreased rate of complications and operative mortality. There is no clear association of long-term survival with spleen and pancreas preservation in D2 lymph node dissection.
The results of two large RCTs from Europe examining extended lymphadenectomy argued that the increased morbidity and mortality observed in these trials was attributable to splenectomy and distal pancreatectomy [1, 2] . Since these conclusions were based on post-hoc subgroup analysis, they must be carefully interpreted. The morbidity and mortality of D2 resections in these trials were much higher than in Asian centers, and thus, some have argued that the European trials may have been biased against long-term benefit by short-term mortality from complications of splenectomy and distal pancreatectomy. Subsequently, a multicenter RCT performed by the Italian Gastric Cancer Study Group (IGCSG) reported improved operative morbidity and mortality, with no difference in short-term outcomes for D1 and D2 lymphadenectomy [32] . In the IGCSG trial, splenectomy was performed only for cancers in the upper left of the stomach or near the greater curvature, and pancreatectomy was not routine [32] . Improvements in short-term outcomes have been Significance corresponds to the noted superscripts AL anastomotic leakage, NR not reported, NS not significant, PF pancreatic fistula, PP pancreas-preserving, PR pancreaticosplenectomy, pts patients, R0 resection with no residual tumor, RR relative risk, SP spleen-preserving, SR splenectomy * Significance when comparing removal of organs in both D1 ? D2 versus no removal in D1 ? D2 attributed to advances in patient selection, perioperative care, surgeon training, surgeon and hospital volume, and quality control [32] . Csendes et al. [26] conducted an RCT comparing extended lymphadenectomy with and without splenectomy, and found that despite some increase in postoperative complications, there was no difference in operative mortality or overall 5-year survival. Similar results were found in the RCT by Yu et al. [28] , with no statistically significant difference in operative mortality or overall 5-year survival, despite an increase in some complications. Both RCTs showed a trend towards increased overall 5-year survival with resection of the spleen. The study by Okinaga et al. [30] was comparatively much smaller, and again, no significant difference in overall survival with spleen preservation was demonstrated. Furukawa et al. [27] also found no statistically significant increase in the reported fistula or leaks rate, and no difference in overall survival in patients who underwent pancreas-preserving D2 lymphadenectomy compared to traditional D2 lymphadenectomy. One potential explanation for these findings is that these trials were inadequately powered to detect a difference. Three of the four trials did not provide power calculations [26, 27, 30] . Power calculations were performed by Yu et al. [28] ; however, patient numbers were adequate to only detect a 20% difference in survival with a power of 80%. Another explanation is that there may yet be a more specific subgroup that does have improved outcomes with resection of the spleen and/or pancreas, but this was undetectable in the midst of other improperly selected patients. The Japan Clinical Oncology Group multicenter RCT, comparing gastrectomy with or without spleen preservation, has completed accrual, and final results are expected when the 5-year survival data are available [13, 52] . This trial was designed as a non-inferiority study powered to detect differences in overall survival and will have 250 patients in each arm [52] . Ideally, this large trial will be able to identify which subgroups, if any, may benefit from splenectomy along with extended lymphadenectomy. The possibility that there may be as yet unidentified subgroups that would benefit or alternatively be harmed by splenic and/or pancreatic resection with gastric surgery may also lie in the debated role of the spleen in gastric cancer. The function of the spleen with respect to cancer immunotherapy in patients with gastric cancer was discussed by some of the studies in the review, as the spleen accounts for 25% of the total body lymphoid tissue [12] . The splenic functions include removal of neoplastic cells from the blood stream, as well as contributing to lymphocyte function. The role of the spleen has been described Fig. 2 Meta-analysis of operative mortality for patients undergoing D2 lymphadenectomy in randomized trials of spleen-preservation versus spleen-resection Fig. 3 Meta-analysis of 5-year survival for patients undergoing D2 lymphadenectomy in randomized trials of spleen-preservation versus spleenresection Significance corresponds to the noted superscripts AL anastomotic leakage, N number, NR not reported, PF pancreatic fistula, pts patients, R0 resection with no residual tumor, SP spleenpreserving, SR splenectomy as both enhancing and suppressing the anti-tumor immune response [12, 46] . Okinaga et al. [30] postulated that splenic lymphocytes have a higher cytotoxic activity in early stage cancer, while increased suppressor activity in later stage cancer. They found that advanced stage gastric cancer patients who underwent gastrectomy with splenectomy who were treated with immunotherapy had improved overall survival [30] . Performing splenectomy and distal pancreatectomy during extended lymphadenectomy was thought to have facilitated removal of lymph nodes along the splenic artery and hilum [8, 14, 18] . However, indications for splenectomy and Significance corresponds to the noted superscripts AL anastomotic leakage, N number, NR not reported, NS not significant, PD pancreaticoduodenectomy, PF pancreatic fistula, PP pancreaspreserving, PR pancreaticosplenectomy, pts patients, R0 resection with no residual tumor, SP spleen-preserving, SR splenectomy pancreatectomy in several of the articles included both extended lymphadenectomy and direct invasion [16, 17, 37, 41, 43, 47, 48] . Margin status is a strong prognostic indicator in patients undergoing surgery for gastric cancer, and positive margins are associated with decreased survival [14, 42, 45] . Accordingly, resections of the spleen and/or Significance corresponds to the noted superscripts AL anastomotic leakage, CG conventional gastrectomy, CL chylous leak, met presence of metastasis, MS median survival, N number, NR not reported, NS not significant, PF pancreatic fistula, PP pancreas-preserving, PR pancreaticosplenectomy, pts patients, R0 resection with no residual tumor, SP spleen-preserving, SR splenectomy pancreas in cases where direct invasion is suspected, in the absence of metastatic disease, may be treated with multivisceral resection [12, 14, 19, 42, 43, 45] , though some argue that survival may not be improved with an aggressive surgical approach [21] . Importantly, it is clear that resection of the spleen and pancreas for direct invasion should be considered separately from extended lymphadenectomy with spleen and pancreas preservation. Conclusions drawn from this review must consider the many limitations of the included studies. Most are retrospective case series from single institutions. The potential for publication bias exists as negative studies were not solicited. Furthermore, there may not be complete exclusion of patients who underwent splenectomy or distal pancreatectomy for indications other than lymphadenectomy, including locally invasive disease or secondary to surgical complications, such as bleeding.
Conclusions
Despite the concern about the increased mortality and morbidity of splenectomy and distal pancreatectomy during extended lymphadenectomy for gastric cancer as demonstrated in some studies, more contemporary studies demonstrate that this procedure can still be done safely with low short-term morbidity and mortality for patients undergoing curative surgery for gastric cancer. However, evidence from RCTs demonstrates no difference in the long-term, overall 5-year survival when patients undergo gastrectomy with spleen and pancreas preserving extended lymphadenectomy. Therefore, there is no compelling evidence that even in the face of a center's expertise to safely perform splenectomy and/or distal pancreatectomy during curative intent surgery for gastric cancer, this additional procedure benefits patients in the long-term. Future studies may refine a set of selection criteria for the patients who may benefit from splenectomy and/or distal pancreatectomy. Results from a large, multi-institution Japanese RCT that may ultimately answer this question are pending.
